MTOR and lymphangioleiomyomatosis: Recent advances have shown that mTOR inhibitors, particularly sirolimus, can significantly improve or stabilize lung function, reduce the frequency of pneumothorax and chylous effusions, and delay disease progression in patients with LAM [5, 6].